INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Trading 06-26 10:34:23

74.800

-1.300

-1.71%

High77.450	Low74.400	Vol3.56M
Open76.150	D1 Closing76.100	Amplitude4.01%
Mkt Cap130.00B	Tradable Cap130.00B	Total Shares1.74B
T/O270.25M	T/O Rate0.21%	Tradable Shares1.74B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":74.8,"timestamp":1782441254858,"preClose":76.1,"halted":0,"volume":3563843,"delay":0,"changeRate":-0.01708278580814714,"floatShares":1738000000,"shares":1738000000,"eps":0.5414458356818556,"marketStatus":"Trading","change":-1.3,"latestTime":"06-26 10:34:23","open":76.15,"high":77.45,"low":74.4,"amount":270248027,"amplitude":0.040079,"askPrice":74.8,"askSize":16000,"bidPrice":74.75,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":0.5414458356818556,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1782446400000},"marketStatusCode":2,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":76.1,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":1.519543,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.544,"impliedVolPercentile":0.6204},"requestUrl":"/m/hq/s/01801/tweets","defaultTab":"tweets","newsList":[{"id":"1112404157","title":"Movement Alert｜Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1112404157","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112404157?lang=en_us&edition=fundamental","pubTime":"2026-06-25 10:03","pubTimestamp":1782352983,"startTime":"0","endTime":"0","summary":"On June 25, Innovent Biologics fell 3.01% in regular trading, trading at 75.35 HKD/share, with turnover of 175 million HKD.On the news front, the company held its annual general meeting on June 24,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646429318","title":"Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of Ibi324 (oln324) in Dme and Wet Amd; Studies Commencing in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646429318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646429318?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:00","pubTimestamp":1782345601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA5HLMMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01801","LU2097828805.USD","LU2328871848.SGD","LU2097828557.USD","HK0000165453.HKD","BK1589","BK1583","LU0455707207.USD","LU0502904849.HKD","LU2242644610.SGD","LU2097828474.EUR","LU2097828631.EUR","LU2097828714.EUR","LU2488822045.USD","BK1161","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646841159","title":"Innovent Biologics Files Directors List with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2646841159","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646841159?lang=en_us&edition=fundamental","pubTime":"2026-06-25 06:17","pubTimestamp":1782339422,"startTime":"0","endTime":"0","summary":"Innovent Biologics files directors list with Hong Kong Stock ExchangeInnovent filed an updated list of directors with the Hong Kong Stock Exchange dated June 25, 2026.Board leadership unchanged, with ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDLc2VtBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","LU2242644610.SGD","BK1583","LU1969619763.USD","BK1161","LU2097828474.EUR","LU0502904849.HKD","BK1589","01801","LU2097828805.USD","LU2097828631.EUR","LU2328871848.SGD","HK0000165453.HKD","LU2097828557.USD","LU2097828714.EUR","01911","LU0455707207.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645921718","title":"Ollin Raises $330 Million to Fund Late-stage Eye Disease Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2645921718","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645921718?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:00","pubTimestamp":1782298800,"startTime":"0","endTime":"0","summary":"Ollin raises $330 million to fund late-stage eye disease drug trialsJune 24 (Reuters)-Texas-based biotech Ollin Biosciences said on Wednesday it has raised $330 million in its latest funding round to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nL4N42V0VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","BK1589","BK4585","BK4588","BK4533","LU0455707207.USD","LU2242644610.SGD","TROW","LU2097828474.EUR","LU2097828714.EUR","LU0502904849.HKD","LU2488822045.USD","LU2097828631.EUR","BK1583","SG9999001440.SGD","LU2328871848.SGD","01801","LU2097828557.USD","HK0000165453.HKD","BK4567","LU1969619763.USD","BK4135","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140794164","title":"Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1140794164","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140794164?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:36","pubTimestamp":1782264996,"startTime":"0","endTime":"0","summary":"On June 24, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.3/share, with turnover of HKD 64.46 million. The stock extended gains following the company's announcement that...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187532886","title":"JPMorgan Chase Increases Stake in Innovent Bio by Approximately 1.07 Million Shares at HK$75.40 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1187532886","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187532886?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:17","pubTimestamp":1782213436,"startTime":"0","endTime":"0","summary":"Recent data from the Hong Kong Stock Exchange reveals that on June 17th, JPMorgan Chase acquired an additional 1,068,875 shares of INNOVENT BIO (01801) at a price of HK$75.3978 per share. The total...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2430703251.USD","LU0820562030.AUD","LU0265550946.USD","LU2417539215.USD","LU1548497426.USD","LU0106831901.USD","BK1583","BK4566","LU1244550221.USD","LU0971096721.USD","LU0211326755.USD","LU0942090050.USD","LU1116320737.USD","LU1551013342.USD","LU2237443895.HKD","IE00BZ1G4Q59.USD","LU2244417387.USD","LU1261432733.SGD","LU2552382132.HKD","LU0256863811.USD","JPO","IE0034235188.USD","LU0820561909.HKD","IE00BLSP4239.USD","LU2488822045.USD","JPX","LU2106854487.HKD","JPMO","LU2328871848.SGD","LU2430703178.SGD","IE000M9KFDE8.USD","LU0208291251.USD","LU0976567544.SGD","LU2023250330.USD","LU1496350171.SGD","LU2552382215.SGD","LU2756315318.SGD","LU0345770308.USD","LU1267930490.SGD","LU2097828631.EUR","LU1244550494.USD","LU0203345920.USD","LU2381873111.SGD","LU1145028129.USD","LU0859254822.USD","BK4550","LU0070302665.USD","IE00BKVL7J92.USD","LU0211331839.USD","LU2505996509.AUD","PGF","LU0256863902.USD","LU1969619763.USD","LU0345770993.USD","LU2211815571.USD","BK4504","LU2097828474.EUR","LU2592432038.USD","LU0868494708.USD","BK4585","LU0868494617.USD","LU1720051108.HKD","IE00BN8TJ469.HKD","LU2756315664.SGD","LU0170899867.USD","LU0106261372.USD","LU0006306889.USD","SG9999002232.USD","IE00BWXC8680.SGD","IE00BFXG1179.USD","LU0683600562.USD","LU2357305700.SGD","JPM","LU1551013425.SGD","IE00BDCRKT87.USD","BK4207","LU2264538146.SGD","LU0238689110.USD","LU2242649171.HKD","BK4582","LU2242644610.SGD","LU0310799852.SGD","BK4516","IE00B3S45H60.SGD","BK1589","LU0203347892.USD","LU0345769128.USD","01801","LU0964807845.USD","IE00BJTD4N35.SGD","LU2097828557.USD","LU2456880835.USD","LU0820561818.USD","LU1720051017.SGD","IE00B1BXHZ80.USD","LU0323591593.USD","LU2237443622.USD","LU0215105999.USD","LU0265550359.USD","LU2237443465.HKD","LU0211328371.USD","BK4533","LU2054465674.USD","LU1119994496.HKD","IE0034235295.USD","LU1917777945.USD","LU1974910355.USD","LU0187121727.USD","LU0267386448.USD","LU2462157665.USD","LU0345769631.USD","IE00BLSP4452.SGD","LU0943347566.SGD","LU1914381329.SGD","LU2746668461.USD","IE00B775SV38.USD","LU2237443382.USD","LU2236285917.USD","LU2023250843.SGD","LU1670628061.USD","BK4581","LU1629891620.HKD","SG9999002224.SGD","LU1366192091.USD","LU1670627923.USD","BK4534","LU1280957306.USD","LU2097828805.USD","LU0048584097.USD","LU1064131342.USD","LU1668664300.SGD","LU2213496289.HKD","LU0640476718.USD","LU0496365809.HKD","LU0320765646.SGD","LU1894683264.USD","IE00BJTD4V19.USD","LU2430703095.HKD","LU1496350502.SGD","HK0000165453.HKD","LU2746668974.SGD","LU0320765489.SGD","IE00B1XK9C88.USD","IE00BDRTCR15.USD","LU1244550577.SGD","LU2237443549.SGD","LU1894683348.USD","IE0034235303.USD","EWH","LU2505996681.GBP","IE00BHPRN162.USD","LU0502904849.HKD","LU1988902786.USD","IE00BYXW3230.USD","LU0689472784.USD","LU0455707207.USD","LU0251132253.USD","LU2357627491.SGD","LU0417517546.SGD","LU2237443978.SGD","LU0787776722.HKD","BK4588","LU0211327993.USD","LU1162221912.USD","IE00BBT3K403.USD","IE00BKDWB100.SGD","LU0149725797.USD","LU2552382058.USD","LU0211326839.USD","LU1363072403.SGD","LU2097828714.EUR","LU2023250504.SGD","BK1161","LU1032466523.USD","LU1084165304.USD","LU0882574139.USD","LU1116320901.HKD","IE00BJLML261.HKD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100407015","title":"Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies","url":"https://stock-news.laohu8.com/highlight/detail?id=1100407015","media":"Stock News","labels":["policyRegulatory","economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100407015?lang=en_us&edition=fundamental","pubTime":"2026-06-23 11:46","pubTimestamp":1782186399,"startTime":"0","endTime":"0","summary":"Shares in the innovative drug sector experienced a broad-based rally today.At the time of writing, SSY GROUP (02005) was up 6.93% at HK$2.16, KEYMED BIO-B (02162) gained 4.14% to HK$59.05, HENGRUI...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","BK1515","LU0417516571.SGD","LU2543165471.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0348766576.USD","LU2097828557.USD","LU0348783233.USD","LU0634319403.HKD","LU0348735423.USD","LU1969619763.USD","LU1961090484.USD","LU0359201612.USD","02162","LU0359201885.HKD","02005","LU2778985437.USD","BK1583","LU2097828805.USD","BK1587","06978","LU0348827113.USD","LU2242644610.SGD","BK1589","BK4585","LU0455707207.USD","LU2476274308.USD","159992","BK1191","LU2460026573.USD","LU2097828474.EUR","HK0000165453.HKD","LU0348825331.USD","LU0561508036.HKD","LU0417516902.SGD","LU1794554557.SGD","LU2476274720.SGD","VXUS","LU0417516738.SGD","LU0540923850.HKD","LU0348767384.USD","BK4588","LU2097828714.EUR","LU0348784397.USD","BK1161","LU2328871848.SGD","01276","09939","LU0502904849.HKD","LU2399975544.HKD","LU2488822045.USD","159938","LU1720050803.USD","IE00B5MMRT66.SGD","LU2097828631.EUR","LU1023057109.AUD","09926","01801","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155922794","title":"Movement Alert｜Innovent Biologics Rises 3.32% in Regular Trading, IBI3003 Phase III First Patient Dosing Combined with Biotech Sector Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1155922794","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155922794?lang=en_us&edition=fundamental","pubTime":"2026-06-23 10:01","pubTimestamp":1782180090,"startTime":"0","endTime":"0","summary":"On June 23, Innovent Biologics rose 3.32% in regular trading, trading at 78.4 HKD/share, with turnover of HKD 268 million.On the news front, the company announced that IBI3003, a trispecific antibody...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189194557","title":"Movement Alert｜Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1189194557","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189194557?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:42","pubTimestamp":1782092568,"startTime":"0","endTime":"0","summary":"On June 22, Innovent Biologics fell 3.68% in regular trading, trading at 72.5 HKD/share, with turnover of approximately 80.58 million HKD.The decline was primarily driven by broad sector weakness...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645250011","title":"Innovent doses first patient in Phase 3 China trial of IBI3003 tri-specific antibody for multiple myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2645250011","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645250011?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:00","pubTimestamp":1782086418,"startTime":"0","endTime":"0","summary":"Innovent dosed the first patient in a China Phase 3 trial of IBI3003, a tri-specific antibody for relapsed or refractory multiple myeloma.The study will compare IBI3003 with standard combination regimens, with progression-free survival as the primary endpoint.Early clinical results were already presented in December 2025, showing encouraging responses with manageable safety in heavily pretreated patients.Further dose-optimization results are expected at future medical meetings, supporting the program’s registrational strategy in China.The drug also holds FDA Fast Track status for later-line patients, with a separate US Phase 1/2 study ongoing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL82LZ0z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01911","LU2097828714.EUR","LU2242644610.SGD","LU2097828805.USD","BK1161","BK1589","LU2097828631.EUR","HK0000165453.HKD","LU0455707207.USD","LU2097828474.EUR","LU2488822045.USD","LU2097828557.USD","LU0502904849.HKD","LU1969619763.USD","01801","BK1147","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645011258","title":"Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of Ibi3003(Gprc5d/Bcma/Cd3 Tri-Specific Antibody) for the Treatment of Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2645011258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645011258?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:00","pubTimestamp":1782086401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA3CX6CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2242644610.SGD","LU0502904849.HKD","LU2097828474.EUR","LU2097828805.USD","LU2488822045.USD","BK1589","LU0455707207.USD","01801","LU2097828557.USD","HK0000165453.HKD","BK1583","LU2097828631.EUR","LU2097828714.EUR","BK1161","LU2328871848.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645019635","title":"Innovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2645019635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645019635?lang=en_us&edition=fundamental","pubTime":"2026-06-22 02:22","pubTimestamp":1782066162,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) drew extra attention after presenting fresh clinical and preclinical data on its metabolic and obesity drug pipeline at the 2026 American Diabetes Association Scientific Sessions, highlighting several GLP-1 and amylin candidates.\nSee our latest analysis for Innovent Biologics.\nThe recent clinical updates appear to have come at a time when momentum in Innovent Biologics has been easing. The share price is at HK$76.15 and the 30 day share price return is down...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-could-be-49-below-fair-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-could-be-49-below-fair-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01801","BK1589","LU1969619763.USD","LU2097828557.USD","LU2097828714.EUR","BK1161","LU2328871848.SGD","HK0000165453.HKD","LU0502904849.HKD","LU2097828805.USD","BK1583","LU0455707207.USD","LU2242644610.SGD","LU2488822045.USD","DCF","LU2097828474.EUR","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103077548","title":"Movement Alert｜Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1103077548","media":"Market Focus","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103077548?lang=en_us&edition=fundamental","pubTime":"2026-06-18 10:26","pubTimestamp":1781749617,"startTime":"0","endTime":"0","summary":"On June 18, Innovent Biologics rose 3.07% in regular trading, trading at 77.75 HKD/share, with turnover of approximately 175 million HKD.On the news front, the biotechnology sector rallied broadly,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643273997","title":"Novo Nordisk to seek approval soon to sell Wegovy pill in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2643273997","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643273997?lang=en_us&edition=fundamental","pubTime":"2026-06-16 14:26","pubTimestamp":1781591193,"startTime":"0","endTime":"0","summary":"UPDATE 3-Novo Nordisk to seek approval soon to sell Wegovy pill in ChinaTo seek Chinese approval for Wegovy weight loss pill Novo in race with Eli Lilly in lucrative obesity marketPatent expiry and generics add pressureAdds a CEO quote on competition in paragraph 7By Andrew Silver","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL1N42O05R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823397103.USD","ELIS","LU0320765059.SGD","LLY","LU0516422366.SGD","ELIL","SG9999014914.USD","LU1568876335.HKD","LU0708995153.HKD","LLII","LLYZ","SGXZ99366536.SGD","89988","LU1894683264.USD","PFE","LU0828237510.HKD","LU2237443978.SGD","LU0630378692.HKD","LU1323998911.USD","01801","LU2039709279.SGD","LU0607220059.USD","SG9999001093.SGD","LU0106252389.USD","HBBD.SI","JD","LU1794554557.SGD","89618","LU1960683339.HKD","LU0048388663.USD","LLYX","BABA","LU2211815571.USD","SG9999006597.SGD","LU0384037296.USD","LU0634319403.HKD","IE0002270589.USD","LU1023057109.AUD","LU1048484197.HKD","LU1769817179.HKD","LU2328871848.SGD","09618","09988","ALBmain","IE00B4JS1V06.HKD","LU0594300419.USD","LU0871576103.HKD","LU0029874905.USD","LU1224709979.USD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108730223","title":"INNOVENT BIO Grants 5,000 Share Options and 105,200 Restricted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1108730223","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108730223?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:36","pubTimestamp":1781534193,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (HKEX: 01801) has announced the granting of share-based awards to certain employees.According to a company filing, on June 15, 2026, the firm issued 5,000 share options to one grantee...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU0455707207.USD","LU2097828714.EUR","BK1589","LU2328871848.SGD","BK1583","LU2097828631.EUR","LU2097828557.USD","BK1161","LU2097828805.USD","LU0502904849.HKD","HK0000165453.HKD","LU2488822045.USD","LU2097828474.EUR","LU2242644610.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201495","title":"Innovent grants 105,200 restricted shares under 2024 share plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643201495?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:31","pubTimestamp":1781533896,"startTime":"0","endTime":"0","summary":"Innovent Biologics granted 5,000 stock options under its 2024 share plan on June 15, 2026; exercise price HKD 77.4 per share.Options run for 10 years; vesting split 75% on June 15, 2029, 25% on June 15, 2030, subject to individual performance targets.Issued 105,200 restricted shares to 22 employees at zero cost; implied value about HKD 8.14 million at HKD 77.4 close.Restricted shares vest on the same schedule; vesting levels can be adjusted based on annual performance assessments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 15, 2026, and is solely respon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL1zn67Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","01801","BK1147","BK1161","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","LU2097828805.USD","HK0000165453.HKD","LU2242644610.SGD","BK1583","LU0455707207.USD","LU2097828631.EUR","01911","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104771647","title":"Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1104771647","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104771647?lang=en_us&edition=fundamental","pubTime":"2026-06-15 11:04","pubTimestamp":1781492694,"startTime":"0","endTime":"0","summary":"On June 15, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.7/share, with turnover of HKD 363 million. The stock rebounded after consecutive sessions of decline, driven by dual...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643324256","title":"Innovent Biologics (SEHK:1801) Stock Valuation After Key Obesity Data And Priority Review Cancer Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2643324256","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643324256?lang=en_us&edition=fundamental","pubTime":"2026-06-14 22:16","pubTimestamp":1781446599,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) drew fresh attention after releasing Phase 1 and preclinical data on its metabolic and obesity pipeline at the American Diabetes Association meeting, along with reporting priority-review progress for cancer drug arcotatug tavatecan in China.\nSee our latest analysis for Innovent Biologics.\nThe news from the ADA and the priority review for arcotatug tavatecan arrive as sentiment around Innovent has been mixed, with the share price at HK$76.45, a 1 day share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-valuation-after-key-obesit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-valuation-after-key-obesit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01801","LU2097828714.EUR","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD","LU2097828631.EUR","HK0000165453.HKD","BK1589","LU0455707207.USD","LU1969619763.USD","LU2242644610.SGD","LU2328871848.SGD","LU2097828805.USD","BK1583","LU2097828474.EUR","BK1161","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186735727","title":"Movement Alert｜Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers","url":"https://stock-news.laohu8.com/highlight/detail?id=1186735727","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186735727?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:10","pubTimestamp":1781230227,"startTime":"0","endTime":"0","summary":"On June 12, Innovent Biologics rose 3.22% in regular trading, trading at HK$74.45/share, with turnover of HK$228 million. The stock is rebounding after consecutive trading sessions of decline driven...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642405913","title":"How Investors May Respond To Innovent Biologics (SEHK:1801) Advancing Oral And Extended-Interval GLP-1 Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2642405913","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642405913?lang=en_us&edition=fundamental","pubTime":"2026-06-11 11:23","pubTimestamp":1781148228,"startTime":"0","endTime":"0","summary":"In early June 2026, Innovent Biologics presented new clinical and preclinical data across its obesity and metabolic pipeline at the American Diabetes Association Scientific Sessions, including first-in-human results for its oral GLP-1 receptor agonist IBI3032 and updates on mazdutide and other next-generation candidates.\nA distinctive angle for investors is Innovent’s push into true oral and once-weekly small-molecule GLP-1 therapies, aiming to combine low-dose efficacy with improved...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/how-investors-may-respond-to-innovent-biologics-sehk1801-adv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/how-investors-may-respond-to-innovent-biologics-sehk1801-adv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2488822045.USD","LU1969619763.USD","BK4543","BK4211","LU2097828714.EUR","LU2097828557.USD","LU2097828631.EUR","LU2242644610.SGD","BK4585","ISBC","AIPO","BK4590","AIYY","HK0000165453.HKD","ARTY","AGIX","LU2097828474.EUR","BK4587","BK4528","BK1589","BK4588","BK4023","AI","LU2097828805.USD","LU2328871848.SGD","GLP","01801","BK4551","CHAT","LU0502904849.HKD","LU0455707207.USD","BK1161","BK4144","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":-0.047},{"period":"3month","weight":-0.1099},{"period":"6month","weight":-0.0576},{"period":"1year","weight":-0.0765},{"period":"ytd","weight":-0.002}],"compareEarnings":[{"period":"1week","weight":-0.0354},{"period":"1month","weight":-0.0985},{"period":"3month","weight":-0.0751},{"period":"6month","weight":-0.1062},{"period":"1year","weight":-0.0571},{"period":"ytd","weight":-0.0996}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.110897},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}